Keyword Analysis & Research: elacestrant
Keyword Research: People who searched elacestrant also searched
Search Results related to elacestrant on Search Engine
-
FDA approves elacestrant for ER-positive
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer
WEBOn January 27, 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for postmenopausal women or adult men with ER-positive, HER2-negative,...
DA: 71 PA: 4 MOZ Rank: 23
-
Elacestrant - Wikipedia
https://en.wikipedia.org/wiki/Elacestrant
WEBElacestrant, sold under the brand name Orserdu, is an anticancer medication which is used in the treatment of breast cancer. It is taken by mouth. Elacestrant is an antiestrogen, or an antagonist of the estrogen receptors, the biological …
DA: 97 PA: 94 MOZ Rank: 45
-
US Food and Drug Administration Approval Summary: Elacestrant …
https://ascopubs.org/doi/abs/10.1200/JCO.23.02112?af=R
WEBFeb 21, 2024 · The US Food and Drug Administration (FDA) approved elacestrant for the treatment of postmenopausal women or adult men with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–), estrogen receptor 1 (ESR1)–mutated advanced or metastatic breast cancer with disease progression after at …
DA: 84 PA: 28 MOZ Rank: 6
-
Elacestrant (oral selective estrogen receptor degrader) Versus …
https://ascopubs.org/doi/10.1200/JCO.22.00338
WEBMay 18, 2022 · Elacestrant is a novel, nonsteroidal, oral SERD that degrades the ER alpha in a dose-dependent manner and inhibits estradiol-dependent ER-directed gene transcription and tumor growth in in vitro and in vivo preclinical models, including those harboring ESR1 mutations associated with endocrine resistance. 13-16 Elacestrant …
DA: 55 PA: 75 MOZ Rank: 71
-
Orserdu: Uses, Side Effects, Dosage, Warnings - Drugs.com
https://www.drugs.com/orserdu.html
WEBAug 23, 2023 · Orserdu (elacestrant) tablets are used to treat advanced or metastatic breast cancer that is estrogen receptor-positive, HER2-negative, and also has an ESR1 mutation. It is used in postmenopausal women or adult men with breast cancer that has progressed after being treated with endocrine therapy.
DA: 90 PA: 77 MOZ Rank: 35
-
ER+/HER2- ESR1m mBC Treatment | ORSERDU® (elacestrant)
https://www.orserdu.com/
WEBER+/HER2- ESR1m mBC Treatment | ORSERDU® (elacestrant) The only treatment for postmenopausal women and adult men with ESR1 -mutated ER+/HER2- advanced or metastatic breast cancer. following disease progression on endocrine therapy. Interested in sharing your ORSERDU® story? Call [888-259-1218] to learn more. ORSERDU is different.
DA: 24 PA: 12 MOZ Rank: 27
-
EMERALD Trial: Elacestrant vs Standard Endocrine ... - ASCO Post
https://ascopost.com/issues/january-25-2023/emerald-trial-elacestrant-vs-standard-endocrine-monotherapy-for-advanced-breast-cancer-after-cdk46-inhibition/
WEBBy Alice Goodman. January 25, 2023. Elacestrant —an investigational oral selective estrogen receptor degrader (SERD)—achieved longer progression-free survival vs standard-of-care endocrine monotherapy as second- or third-line therapy in patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer in the ...
DA: 41 PA: 39 MOZ Rank: 61
-
Elacestrant: First Approval - PubMed
https://pubmed.ncbi.nlm.nih.gov/37060385/
WEBIn January 2023, elacestrant received its first approval for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated (as determined by a US FDA-approved test) advanced or metastatic breast cancer with disease progression following ≥ 1 line of endocrine therapy in the USA.
DA: 94 PA: 37 MOZ Rank: 27
-
Elacestrant May Improve Outcomes for Patients Whose …
https://www.aacr.org/about-the-aacr/newsroom/news-releases/elacestrant-may-improve-outcomes-for-patients-whose-metastatic-breast-cancers-progressed-on-prior-endocrine-therapy/
WEBDec 7, 2021 · Elacestrant is an investigational SERD that, unlike fulvestrant, is administered orally. Bardia explained that elacestrant has greater absorption, improved pharmokinetics, and enhanced inhibition of ER compared with fulvestrant.
DA: 7 PA: 57 MOZ Rank: 84
-
Elacestrant: MedlinePlus Drug Information
https://medlineplus.gov/druginfo/meds/a623011.html
WEBElacestrant is used to treat certain types of hormone receptor-positive breast cancer (breast cancer that depends on hormones such as estrogen to grow) in adults who have had disease progression following treatment with at least one other hormone therapies.
DA: 54 PA: 39 MOZ Rank: 64
